| HOME >> BIOLOGY >> TECHNOLOGY |
19,76816,615Write-offs of other intangible assets acquired in acquisitions
-271Unrealized gain on auction rate securities
-(1,714)Unrealized loss on put option
-1,844Deferred rent
1885Changes in operating assets and liabilities:Accounts receivable
(7,830)(4,394)Inventory
(23,982)124Prepaid expenses and other current assets
(237)(1,426)Other non-current assets
(122)(113)Accounts payable and other current liabilities
11,347(5,112)Accrued compensation
5,3343,726Deferred revenue
(2,084)7,062Net cash provided by operating activities
27,03227,343Cash flows from investing activities:Capital expenditures
(18,942)(13,047)Acquisition of leasehold improvements
-125Payments for technology licenses
(1,655)(1,000)Cost of acquisitions, net
(296)(1,300)Proceeds from the sales of short-term investments
-24,800Proceeds from the sale of fixed assets
20138Net cash provided by (used in) investing activities
(20,873)9,716Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options
35,85715,334Proceeds from notes payable
-6,448Principal payment of bank borrowing
-(14,618)Principal payment of notes payable
(6,669)(618)Net cash provided by financing activities
29,1886,546Effect of exchange rate change on cash
123147Net increase in cash and cash equivalents
35,47043,752Cash and cash equivalents at beginning of period
79,53835,786Cash and cash equivalents at end of period
$
5,008$
79,538CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months Ended
December 31,Years Ended
December 31,2011201020112010Cost of product sales$
38,632$
26,570$
22,840$
5,135 Stock compensation expense(443)(687)(1
'/>"/>
| SOURCE Cepheid Copyright©2010 PR Newswire. All rights reserved |